BRUSSELS: The European Union has agreed to pay a premium on new orders of COVID-19 vaccines because it is requiring tougher terms to be met, European officials said, as the bloc tries to protect supplies after a rocky start to its vaccination campaign.
The higher price is less than the United States has agreed to pay in its latest order in July.
On Sunday, the Financial Times reported the EU has agreed to pay Pfizer and BioNTech 19.5 euros ($23.1) for each of their COVID-19 shots under a contract signed in May for up to 1.8 billion doses, up from the 15.5 euros per dose under two initial supply contracts for a total of 600 million vaccines.
The price for Moderna shots went up to $25.5 a dose, the newspaper said, referring to a 300 million vaccine deal, up from $22.6 in its initial deal for 160 million jabs.
EU lawmaker Tiziana Beghin, a member of Italy's 5-star ruling party, said the EU was being been ripped off.
"It's inexplicable," she said.
Moderna's price is still at the lowest end of the $25-$37 range indicated by the company last year, but Pfizer and BioNTech had previously said prices would be lower for bigger volume deals.
Others said there were good reasons to pay more and that circumstances had changed greatly from when initial deals were struck with drugmakers last year.
France's European affairs minister Clement Beaune told French radio RFI on Monday the likely higher prices were still under negotiation and were the result of stricter clauses on variants, production and deliveries.
One European official familiar with negotiations with vaccine makers said the value of the drugmakers' shots had risen since evidence had emerged of their efficacy and of the positive impact they had on helping the economy to recover from a pandemic-induced recession.
"Several factors played a role," the official said, speaking on condition of anonymity.
BARGAINING POWER
All the vaccines used in Europe have been shown to have a beneficial impact, but those made by AstraZeneca and Johnson & Johnson, have faced restrictions on their use in the EU because of concerns they can in rare instances lead to blood clots.
Those two vaccine makers have also suffered supply problems, which in the case of AstraZeneca have led to legal challenges by the EU.
While the bargaining power of Pfizer/BioNTech and Moderna has increased, additional EU demands are likely to raise the costs of making and delivering vaccines.
A spokesman for Pfizer declined to comment on the European prices, but said the latest contract with the EU was different from the initial ones, including on matters concerning production and delivery.
Moderna did not respond to a request for comment.
The European Commission, which coordinates negotiations with vaccine makers together with EU governments' representatives, declined to comment for this story, citing confidentiality clauses.
Earlier this year, lawmakers, media and some analysts criticised the bloc for paying too little for the early supplies of COVID-19 vaccines, saying that had contributed to initial delays in the vaccination drive.
"It's easy to criticise the EU because it spends little and late or because it spends too much," said Giovanna De Maio, non-resident fellow at the Brookings Institution, a U.S. research group.
"Reality is much more complicated, and perhaps it is correct to give priority to access to vaccines rather than costs given the pace at which the Delta variant is spreading," she added, referring to the more transmissible variant that was first detected in India.
On July 23, Washington bought an additional 200 million vaccines from Pfizer at a price of $24 a dose (20.1 euros), the company said, up from $19.5 the United States paid for its first 300 million shots.
Pfizer said the higher U.S. prices reflected investment needed to produce, package and deliver new formulations of the vaccine, as well as extra costs in producing smaller pack sizes suited to "individual provider offices, including pediatricians".
MADE IN THE EU
When the EU agreed in May its third supply deal with Pfizer for up to 1.8 billion doses, the Commission said the new contract required the vaccines to be made in the EU and the essential components to be sourced from the region.
In its first supply deals, the EU had required that only vaccines were made in the EU, not their components.
Concentrating production in Europe can help guarantee supply now that production lines are well established and there is less need for leeway, but it is also likely to increase costs.
The EU Commission also said in its statement that under the new contract "from the start of the supply in 2022, the delivery to the EU is guaranteed," whereas under the first contract Pfizer was only required to make its "best reasonable efforts" to ship pre-agreed volumes by set deadlines.
Pfizer has so far respected its commitments to the EU, and has delivered slightly more than initially planned in the first quarter of the year.
Another big change since the early contracts is the emergence of variants and concerns vaccines may not be effective against them.
EU officials said governments could refuse to buy shots that did not protect against variants, while companies will be expected to quickly adapt their vaccines, potentially at significant cost.
($1 = 0.8422 euros)
Reuters
Tue Aug 03 2021
The higher price is less than the United States has agreed to pay in its latest order in July. REUTERS photo
LIMA '25 pada 20-24 Mei 2025, ketengah kepentingan pemain industri
Timbalan Menteri Pertahanan Adly Zahari berkata LIMA '25 di pulau peranginan Langkawi, Kedah itu bertemakan Innovate Today, Thrive Tomorrow.
Najib diberi peluang jelaskan mengenai dokumen 1MDB ketika disoal siasat - Pegawai SPRM
Mahkamah Tinggi diberitahu bahawa Najib diberi peluang untuk menjelaskan secara terperinci mengenai dokumen berkaitan 1MDB, ketika disoal siasat.
Pantau Agenda Reformasi: Penstrukturan akaun & pengenalan akaun 3 KWSP
Ikuti kupasan penganalisis ekonomi Pusat Pengajian Siswazah Perniagaan, Universiti Tun Abdul Razak (UNIRAZAK), Prof. Emeritus Barjoyai Bardai mengenai penstrukturan akaun KWSP & pengenalan akaun 3.
Pihak dikaitkan dalam laporan berkaitan lesen kasino perlu ambil tindakan - PM Anwar
Laporan yang memetik satu sumber itu berkata perbincangan mengenai pemberian lesen itu masih di peringkat awal.
Freedom Flotilla to Gaza: 'Berhadapan tekanan Israel, FCC tiada istilah putus asa'
Pemeriksaan kapal penumpang, Akdeniz (Mediterranean) yang terlibat dalam misi Break The Siege Freedom Flotilla to Gaza dilaporkan sedang berjalan.
Niaga AWANI: Airasia Group bakal disenaraikan di Bursa Malaysia pada September - Tony Fernandes
AirAsia Group Sdn Bhd (AAG) bakal disenaraikan di Bursa Malaysia pada September, mengambil alih status penyenaraian AirAsia X Bhd, kata Ketua Pegawai Eksekutif Capital A Bhd Tan Sri Tony Fernandes.fernandes, bursa Malaysia.
#NiagaAWANI
#NiagaAWANI
Niaga AWANI: Bekas CEO 7-Eleven, Hishammudin Hasan dilantik terajui Al-Ikhsan
Al-Ikhsan Sports Sdn Bhd, firma swasta dengan 35% pegangan milik
Ekuiti Nasional Bhd (Ekuinas) telah melantik Datuk Hishammudin Hasan sebagai ketua pegawai eksekutif (CEO) baharunya berkuat kuasa 17 April 2024.
#NiagaAWANI
Ekuiti Nasional Bhd (Ekuinas) telah melantik Datuk Hishammudin Hasan sebagai ketua pegawai eksekutif (CEO) baharunya berkuat kuasa 17 April 2024.
#NiagaAWANI
Niaga AWANI: MOT, KHAZANAH, MAG perlu perkukuh tadbir urus MAB
Jelas Perdana Menteri, pengurusan syarikat penerbangan yang baik juga akan memberi manfaat kepada kakitangan melalui gaji yang setimpal dengan perkhidmatan mereka.
#NiagaAWANI
#NiagaAWANI
Niaga AWANI: Vincent Tan tak terbabit rundingan lesen kasino Forest City
Berjaya Corp Bhd (BCorp) menafikan laporan yang mengaitkan Pengasasnya, Tan Sri Vincent Tan terbabit dalam rundingan berkaitan lesen kasino di Forest City, Johor.
#NiagaAWANI
#NiagaAWANI
Niaga AWANI: Kadar antara bank jangka pendek ditutup kukuh susulan operasi BNM
Kadar antara bank jangka pendek ditutup kukuh pada Jumaat susulan operasi Bank Negara Malaysia (BNM) menyerap lebihan mudah tunai daripada sistem kewangan.
#NiagaAWANI
#NiagaAWANI
Kelaparan akut jejaskan 281.6 juta orang tahun lepas - PBB
Tahap bahaya kelaparan akut menjejaskan 281.6 juta orang tahun lepas, tahun kelima berturut-turut bahawa ketakjaminan makanan semakin memburuk.
Hamilton optimis kedudukan lebih baik di GP China
Lewis Hamilton melihat potensi kedudukan yang lebih baik dalam saingan Grand Prix yang kembali ke China buat pertama kali dalam tempoh lima tahun, hujung minggu ini.
'Selfish!' - Fasha Sandha sedih raya di Perlis tak jadi gara-gara dijangkiti COVID-19
Fasha berkata dia mula melakukan pemeriksaan COVID-19 selepas berasa tidak sihat badan dan mengalami bersin tidak henti sejak Raya pertama.
Kes COVID-19 catat penurunan ketara pada ME 14/2024 - KKM
Jumlah kes COVID-19 menurun 97.1 peratus kepada 493 kes pada Minggu Epidemiologi ke-14 (ME 14/2024) iaitu bagi tempoh 31 Mac hingga 6 April lepas berbanding 17,256 kes pada ME 1/2024.
China jadikan pengalaman pencegahan COVID-19 untuk hadapi pandemik masa depan
China akan menjadikan pengalaman dalam pencegahan dan kawalan COVID-19 untuk membuat persediaan yang lebih proaktif untuk menghadapi pandemik masa depan seperti "Penyakit X".
Negara berdepan ketirisan subsidi diesel serius - Amir Hamzah
Negara kini sedang berdepan isu ketirisan subsidi diesel yang serius dan wujud kemungkinan terdapat pihak yang tidak layak masih menikmati subsidi itu, kata Menteri Kewangan II Datuk Seri Amir Hamzah.
Kematian akibat kemalangan jalan raya lebih tinggi daripada COVID-19 - Anthony Loke
PDRM akan mengeluarkan data mengenai kemalangan jalan raya pada setiap hari, bukan setahun sekali seperti diamalkan sebelum ini.
Ismail Sabri ziarah lapan beradik yatim piatu akibat COVID-19
Ismail Sabri tiba kira-kira jam 2 petang di kediaman lapan beradik itu di Taman Adenium, Bukit Beruntung pada Selasa.
Teori konspirasi 'Penyakit X'
Ahli teori konspirasi AS sekali lagi membuat 'keuntungan' selepas PBB memberi amaran tentang wabak lebih berbahaya iaitu 'Penyakit X'.
Reformasi dasar, kukuhkan perlindungan, produktiviti pekerja tidak formal
Reformasi dasar perlu dilakukan dalam usaha meningkatkan perlindungan dan produktiviti pekerja tidak formal di Malaysia.